Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
Open Access
- 13 April 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (28) , 19817-19825
Abstract
Oncotarget | https://doi.org/10.18632/oncotarget.24865 Tomohiro Kondo, Masashi Kanai, Tadayuki Kou, Tomohiro Sakuma, Hiroaki Mochizuki, Mayumi Kamada, Masahiko Nakatsui, Norimitsu Uza, Yuzo Kodama, Toshihiko... Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancerKeywords
This publication has 20 references indexed in Scilit:
- Germline mutations in pancreatic cancer and potential new therapeutic optionsOncotarget, 2017
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based ChemotherapyJournal of Clinical Oncology, 2016
- BRCAness revisitedNature Reviews Cancer, 2016
- Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2015
- Whole genomes redefine the mutational landscape of pancreatic cancerNature, 2015
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 TrialJournal of Clinical Oncology, 2014
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersBritish Journal of Cancer, 2014
- Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal CarcinomasClinical Cancer Research, 2014
- An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future DirectionsThe Oncologist, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011